Cargando…
Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
BACKGROUND/AIMS: To investigate the autoantibody against fumarate hydratase (FH), which is a specific liver failure-associated antigen (LFAA) and determine whether it can be used as a biomarker to evaluate the prognosis of acute-on-chronic liver failure (ACLF). METHODS: An immunoproteomic approach w...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502492/ https://www.ncbi.nlm.nih.gov/pubmed/36317513 http://dx.doi.org/10.5009/gnl220022 |
_version_ | 1785106333813440512 |
---|---|
author | Wei, Linlin Wang, Ting Chen, Sisi Liu, Yeying Huang, Xueying Zheng, Sujun Xu, Bin Ren, Feng Liu, Mei |
author_facet | Wei, Linlin Wang, Ting Chen, Sisi Liu, Yeying Huang, Xueying Zheng, Sujun Xu, Bin Ren, Feng Liu, Mei |
author_sort | Wei, Linlin |
collection | PubMed |
description | BACKGROUND/AIMS: To investigate the autoantibody against fumarate hydratase (FH), which is a specific liver failure-associated antigen (LFAA) and determine whether it can be used as a biomarker to evaluate the prognosis of acute-on-chronic liver failure (ACLF). METHODS: An immunoproteomic approach was applied to screen specific LFAAs related to differential prognosis of ACLF (n=60). Enzyme-linked immunosorbent assay (ELISA) technology was employed for the validation of the frequency and titer of autoantibodies against FH in ACLF patients with different prognoses (n=82). Moreover, we clarified the expression of autoantibodies against FH in patients with chronic hepatitis B (n=60) and hepatitis B virus-related liver cirrhosis (n=60). The dynamic changes in the titers of autoantibodies against FH were analyzed by sample collection at multiple time points during the clinical course of eight ACLF patients with different prognoses. RESULTS: Ultimately, 15 LFAAs were screened and identified by the immunoproteomic approach. Based on ELISA-based verification, anti-FH/Fumarate hydratase protein autoantibody was chosen to verify its expression in ACLF patients. ACLF patients had a much higher anti-FH autoantibody frequency (76.8%) than patients with liver cirrhosis (10%, p=0.000), patients with chronic hepatitis B (6.7%, p=0.022), and normal humans (0%, p=0.000). More importantly, the frequency and titer of anti-FH protein autoantibodies in the serum of ACLF patients with a good prognosis were much higher than that of patients with a poor prognosis (83.9% vs 61.5%, p=0.019; 1.41±0.85 vs 0.94±0.56, p=0.017, respectively). The titer of anti-FH autoantibodies showed dynamic changes in the clinical course of ACLF. CONCLUSIONS: The anti-FH autoantibody in serum may be a potential biomarker for predicting the prognosis of ACLF. |
format | Online Article Text |
id | pubmed-10502492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial Office of Gut and Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-105024922023-09-16 Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure Wei, Linlin Wang, Ting Chen, Sisi Liu, Yeying Huang, Xueying Zheng, Sujun Xu, Bin Ren, Feng Liu, Mei Gut Liver Original Article BACKGROUND/AIMS: To investigate the autoantibody against fumarate hydratase (FH), which is a specific liver failure-associated antigen (LFAA) and determine whether it can be used as a biomarker to evaluate the prognosis of acute-on-chronic liver failure (ACLF). METHODS: An immunoproteomic approach was applied to screen specific LFAAs related to differential prognosis of ACLF (n=60). Enzyme-linked immunosorbent assay (ELISA) technology was employed for the validation of the frequency and titer of autoantibodies against FH in ACLF patients with different prognoses (n=82). Moreover, we clarified the expression of autoantibodies against FH in patients with chronic hepatitis B (n=60) and hepatitis B virus-related liver cirrhosis (n=60). The dynamic changes in the titers of autoantibodies against FH were analyzed by sample collection at multiple time points during the clinical course of eight ACLF patients with different prognoses. RESULTS: Ultimately, 15 LFAAs were screened and identified by the immunoproteomic approach. Based on ELISA-based verification, anti-FH/Fumarate hydratase protein autoantibody was chosen to verify its expression in ACLF patients. ACLF patients had a much higher anti-FH autoantibody frequency (76.8%) than patients with liver cirrhosis (10%, p=0.000), patients with chronic hepatitis B (6.7%, p=0.022), and normal humans (0%, p=0.000). More importantly, the frequency and titer of anti-FH protein autoantibodies in the serum of ACLF patients with a good prognosis were much higher than that of patients with a poor prognosis (83.9% vs 61.5%, p=0.019; 1.41±0.85 vs 0.94±0.56, p=0.017, respectively). The titer of anti-FH autoantibodies showed dynamic changes in the clinical course of ACLF. CONCLUSIONS: The anti-FH autoantibody in serum may be a potential biomarker for predicting the prognosis of ACLF. Editorial Office of Gut and Liver 2023-09-15 2022-11-01 /pmc/articles/PMC10502492/ /pubmed/36317513 http://dx.doi.org/10.5009/gnl220022 Text en Copyright © Gut and Liver. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Wei, Linlin Wang, Ting Chen, Sisi Liu, Yeying Huang, Xueying Zheng, Sujun Xu, Bin Ren, Feng Liu, Mei Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure |
title | Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure |
title_full | Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure |
title_fullStr | Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure |
title_full_unstemmed | Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure |
title_short | Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure |
title_sort | serum anti-fumarate hydratase autoantibody as a biomarker for predicting prognosis of acute-on-chronic liver failure |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502492/ https://www.ncbi.nlm.nih.gov/pubmed/36317513 http://dx.doi.org/10.5009/gnl220022 |
work_keys_str_mv | AT weilinlin serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT wangting serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT chensisi serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT liuyeying serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT huangxueying serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT zhengsujun serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT xubin serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT renfeng serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure AT liumei serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure |